Moreover, our findings suggested that the inhibition of PI3K/AKT signaling might account for the anti-CRC ability of cincumol in vitro, that was to say, cincumol was a potential anti-CRC drug that had the potential to be applied in clinical treatment. Here, AKT1 is linked to colorectal carcinoma.